500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Prospectus Supplement Filed for $200 Million Common Stock Offering
Stockholders Elect Clare Kahn, Adam Stone, and Lynne Sullivan as Directors
Annual Report to Security Holders
Director Resignation and Appointment - Ilan Ganot Moves to Class I
Material disclosure
Solid Biosciences Inc. Enters $84 Million Securities Purchase Agreement
Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
News
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload